:--------------------------:
: OMB APPROVAL :
:--------------------------:
:OMB Number: 3235-0145:
UNITED STATES :Expires: November 30, 1999
SECURITIES AND EXCHANGE COMMISSION :Estimated average burden :
WASHINGTON, D.C. 20549 :hours per response . 14.90:
:--------------------------:
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Duramed Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $0.01 Per Share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
266354 10 9
-------------------------------------------------------
(CUSIP Number)
Jeffrey D. Linton
Vice President, Law, Government and
Public Affairs
Solvay Pharmaceuticals, Inc.
901 Sawyer Road
Marietta, Georgia 30062
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
October 22, 1999
-------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box [_].
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss. 240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SEC 1746(12-91)
<PAGE>
SCHEDULE 13D
- --------------------- ------------------
CUSIP NO. 266354 10 9 Page 2 of 7 Pages
- --------------------- ------------------
- -------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Solvay Pharmaceuticals, Inc.
- -------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [_]
(SEE INSTRUCTIONS) (B) [_]
- -------------------------------------------------------------------------------
3. SEC USE ONLY
- -------------------------------------------------------------------------------
4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
- -------------------------------------------------------------------------------
5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
- -------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Georgia
- -------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER
SHARES 1,666,666
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8. SHARED VOTING POWER
EACH -0-
REPORTING --------------------------------------------------------------
PERSON 9. SOLE DISPOSITIVE POWER
WITH 1,666,666
--------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,666,666
- -------------------------------------------------------------------------------
12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [X]
- -------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.1%
- -------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------
<PAGE>
SCHEDULE 13D
- --------------------- ------------------
CUSIP NO. 266354 10 9 Page 3 of 7 Pages
- --------------------- ------------------
- -------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Solvay America, Inc.
- -------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [_]
(SEE INSTRUCTIONS) (B) [_]
- -------------------------------------------------------------------------------
3. SEC USE ONLY
- -------------------------------------------------------------------------------
4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- -------------------------------------------------------------------------------
5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
|_|
- -------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER
SHARES 1,666,666
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8. SHARED VOTING POWER
EACH -0-
REPORTING --------------------------------------------------------------
PERSON 9. SOLE DISPOSITIVE POWER
WITH 1,666,666
--------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,666,666
- -------------------------------------------------------------------------------
12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [X]
- -------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.1%
- -------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------
<PAGE>
SCHEDULE 13D
- --------------------- ------------------
CUSIP NO. 266354 10 9 Page 4 of 7 Pages
- --------------------- ------------------
- -------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Solvay S.A.
- -------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [_]
(SEE INSTRUCTIONS) (B) [_]
- -------------------------------------------------------------------------------
3. SEC USE ONLY
- -------------------------------------------------------------------------------
4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
- -------------------------------------------------------------------------------
5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
- -------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Belgium
- -------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER
SHARES 1,666,666
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8. SHARED VOTING POWER
EACH -0-
REPORTING --------------------------------------------------------------
PERSON 9. SOLE DISPOSITIVE POWER
WITH 1,666,666
--------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,666,666
- -------------------------------------------------------------------------------
12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [X]
- -------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.1%
- -------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
HC, OO
- -------------------------------------------------------------------------------
<PAGE>
CUSIP Number: 266354 10 9 Page 5 of 7
Solvay Pharmaceuticals, Inc., a Georgia corporation ("Solvay
Pharmaceuticals"), Solvay America, Inc., a Delaware corporation ("Solvay
America") and Solvay S.A., a Belgian societe anonyme ("Solvay S.A." and together
with Solvay Pharmaceuticals and Solvay America, the "Reporting Persons") hereby
amend the Report of Beneficial Ownership on Schedule 13D (the "Original Schedule
13D") filed by the Reporting Persons on October 18, 1999 and the first amendment
to the Original Schedule 13D (the "Amended Schedule 13D"), filed October 21,
1999, with respect to shares of Common Stock, par value $.01 per share (the
"Shares"), of Duramed Pharmaceuticals, Inc., a Delaware corporation ("Duramed")
beneficially owned by them. Capitalized terms used but not defined herein shall
have the meaning attributed to such terms in the Original Schedule 13D or the
Amended Schedule 13D.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Item 3 is amended as follows:
On October 22, 1999, Solvay Pharmaceuticals purchased 1,666,666 Shares
of Duramed at a price of $9.00 per share pursuant to the Initial Subscription
Agreement. Solvay paid the aggregate purchase price of $14,999,994 using readily
available funds from its working capital.
ITEM 4. PURPOSE OF TRANSACTION
Item 4 is amended as follows:
On October 21, 1999 the boards of directors of Solvay Pharmaceuticals
and Solvay America approved the Subsequent Subscription Agreement. Approval by
the boards of directors of Solvay Pharmaceuticals and Solvay America was a
condition to consummation of the purchase contemplated by the Subsequent
Subscription Agreement.
On October 22, 1999, Solvay Pharmaceuticals purchased 1,666,666 Shares
of Duramed at a purchase price of $9.00 per Share pursuant to the Initial
Subscription Agreement. Moreover,
<PAGE>
CUSIP Number: 266354 10 9 Page 6 of 7
as contemplated by the Initial Subscription Agreement, Duramed and Solvay
Pharmaceuticals entered into the Initial Registration Rights Agreement attached
to the Amended Schedule 13D as Exhibit E.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS
WITH RESPECT TO SECURITIES OF THE ISSUER
Item 6 is amended as follows:
On October 21, 1999 the boards of directors of Solvay Pharmaceuticals
and Solvay America approved the Subsequent Subscription Agreement. Approval by
the boards of directors of Solvay Pharmaceuticals and Solvay America was a
condition to consummation of the purchase contemplated by the Subsequent
Subscription Agreement.
On October 22, 1999, Solvay Pharmaceuticals purchased 1,666,666 Shares
of Duramed at a purchase price of $9.00 per Share pursuant to the Initial
Subscription Agreement. Moreover, as contemplated by the Initial Subscription
Agreement, Duramed and Solvay Pharmaceuticals entered into the Initial
Registration Rights Agreement attached to the Amended Schedule 13D as Exhibit E.
<PAGE>
CUSIP Number: 266354 10 9 Page 7 of 7
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief,
we certify that the information set forth in this statement is true, complete
and correct.
Dated: October 25, 1999
SOLVAY PHARMACEUTICALS, INC.
By: /s/ Jeffrey D. Linton
------------------------------
Name: Jeffrey D. Linton
Title: Vice President, Law,
Government and Public
Affairs
SOLVAY AMERICA, INC.
By: /s/ E.J. Buckingham, III
------------------------------
Name: E.J. Buckingham, III
Title: Vice President, General
Counsel and Secretary
SOLVAY S.A.
By: /s/ Rene H. Degreve
------------------------------
Name: Rene H. Degreve
Title: General Manager, Finance
and Corporate Planning
<PAGE>
INDEX TO EXHIBITS
Exhibit No. Exhibit
- ----------- -------
99.2 Joint Filing Statement, dated as of October 15, 1999, between
Solvay Pharmaceuticals, Inc., Solvay America, Inc. and Solvay
S.A. (incorporated by reference to Exhibit 99.2 of the Report
of Beneficial Ownership on Schedule 13D, filed with the
Securities and Exchange Commission on October 18, 1999).
99.5 Form of Registration Rights Agreement among Duramed
Pharmaceuticals, Inc. and Solvay Pharmaceuticals, Inc.
(regarding the registration rights attached to Solvay
Pharmaceuticals' initial purchase of 1,666,666 Shares of
Duramed) (incorporated by reference to Exhibit 99.5 of the
First Amendment to the Report of Beneficial Ownership on
Schedule 13D, filed with the Securities and Exchange
Commission on October 21, 1999).
